Your Search Results

Radial and distal radial artery access for PCI

19 May 2026 – From EuroPCR 2026

This session provides an in-depth evaluation of radial and distal radial artery access for PCI, including a 20-year trend analysis of clinical outcomes, feasibility studies on distal radial interventions, and comparative real-world experiences. It also features meta-analyses of randomized trials on access approaches and early findings...

Devices and strategies in calcified lesions

21 May 2026 – From EuroPCR 2026

Explore advanced devices and techniques for treating calcified coronary lesions in this session. Discussions include the use of Eximer laser coronary atherectomy, novel cutting balloons, outcomes of rotational atherectomy in tortuous vessels, atherectomy combined with drug-coated balloon therapy, and calcium fracture patterns following Shockwave intravascular lithotripsy.

Treatment for calcified coronary artery disease in the real world

19 May 2026 – From EuroPCR 2026

This session presents real-world experiences and evidence on treating calcified coronary artery disease. It includes meta-analyses comparing rotational atherectomy and balloon angioplasty, long-term outcomes of excimer laser atherectomy, and multicenter registry data on intravascular lithotripsy (IVL), particularly in diabetic and high-risk patients. The session also focuses...

Addressing difficult anatomy in STEMI patients

21 May 2026 – From EuroPCR 2026

This session addresses the challenges of managing difficult coronary anatomy in STEMI patients through a series of complex case studies. Topics include management of aneurysms, rare aorto-ostial lesions, thrombosis interplay, PPCI in dextrocardia situs inversus, and hybrid PCI approaches for multifaceted coronary issues.

TAVI complications: impact and improvement

20 May 2026 – From EuroPCR 2026

This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.

INOCA/ANOCA: technical aspects

20 May 2026 – From EuroPCR 2026

This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...

FFR and non-hyperaemic pressure ratios

20 May 2026 – From EuroPCR 2026

This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.

Other right-sided and tricuspid valve interventions

20 May 2026 – From EuroPCR 2026

This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.

POPular PAUSE TAVI - Continuation or interruption of oral anticoagulation during TAVI?

02 Sep 2024

Luis Ortega-Paz provides his take on the POPular PAUSE TAVI trial presented by Dirk Jan van Ginkel at the ESC Congress 2024 in London.

Author

Luis Ortega-Paz

OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease

04 Nov 2021

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

Author

Mirvat Alasnag

OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Best of #AHA21 Scientific Sessions: coronary and valvular heart disease trials

14 Nov 2021

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Author

Vijay Kunadian

ESC/EACTS Valvular Heart Disease Guidelines 2021: updates from the 2017 Guidelines

29 Aug 2021

There has been significant expansion in the field of structural heart diseases in the last couple of years, generating an extensive body of evidence and warranting an update to the 2017 Guidelines. Mirvat Alasnag provides an analysis of the updates included in this new document - a joint...

Author

Mirvat Alasnag

Evidence base: current data on TAVI durability and long-term outcomes

18 Jun 2026

This article reviews the current evidence on TAVI durability, focusing on long-term outcomes, device-specific considerations, and the implications for lifetime management strategies.